- Home
- QNRX vs HSCS Comparison
QNRX vs HSCS Comparison
Compare QNRX & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNRX | HSCS |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 9.5M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | QNRX | HSCS |
|---|---|---|
| Price | $8.15 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.20 |
| AVG Volume (30 Days) | ★ 20.9K | 8.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,072.41 |
| Revenue Next Year | N/A | $2,700.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $2.01 |
| 52 Week High | $41.80 | $6.47 |
Technical Indicators
Market Signals| Indicator | QNRX | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 38.40 |
| Support Level | $8.03 | $2.16 |
| Resistance Level | $10.10 | $3.28 |
| Average True Range (ATR) | 0.50 | 0.11 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 12.09 | 21.59 |
Price Performance
Historical ComparisonAbout QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.